Odonate Therapeutics, Inc.
ODTC · OTC
12/31/2022 | 9/30/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $53 | $0 | $256 | $264 |
| Gross Profit | -$53 | $0 | -$256 | -$264 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $2,869 |
| G&A Expenses | $0 | $0 | $0 | $1,206 |
| SG&A Expenses | $385 | $2,386 | $3,040 | $1,206 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$292 |
| Operating Expenses | $385 | $2,386 | $3,040 | $3,783 |
| Operating Income | -$438 | -$2,386 | -$3,296 | $12,346 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6,251 | $7,217 | $4,761 | -$26,343 |
| Pre-Tax Income | $5,813 | $4,831 | $1,465 | -$13,997 |
| Tax Expense | $1,062 | -$34,364 | $0 | $0 |
| Net Income | $4,751 | $39,195 | $1,465 | -$13,997 |
| % Margin | – | – | – | – |
| EPS | 4,330.567 | 36,411.025 | 1,287.871 | -9,841.349 |
| % Growth | -88.1% | 2,727.2% | 113.1% | – |
| EPS Diluted | 4,330.567 | 36,349.698 | 1,287.871 | -9,841.349 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $53 | $27 | $256 | $244 |
| EBITDA | $5,866 | $4,858 | -$2,997 | -$13,753 |
| % Margin | – | – | – | – |